Abstract

Clinical Pharmacology & Therapeutics (2003) 73, P64–P64; doi:

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
“Black box” 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk
Rosemary Roberts ... Shirley Murphy
The Journal of Allergy and Clinical Immunology | VOL. 117
Rosemary Roberts, et. al.Rosemary Roberts ... Shirley Murphy
29 Dec 2005
FDA's role in anesthetic drug development.
Roberta C. Kahn ... Laurence Landow
Anesthesiology | VOL. 90
Roberta C. Kahn, et. al.Roberta C. Kahn ... Laurence Landow
01 Mar 1999
Successful Investigational New Drug Preparation without Reinventing the Wheel
Emily S. Gorell ... Andrea L. Tichy
Journal of Investigative Dermatology | VOL. 131
Emily S. Gorell, et. al.Emily S. Gorell ... Andrea L. Tichy
01 May 2011
Best Practices for Communication between FDA and Applicants during the NDA Review Cycle: A PhRMA White Paper
Donna Peterson ... Jennifer L. Stotka
Drug Information Journal | VOL. 42
Donna Peterson, et. al.Donna Peterson ... Jennifer L. Stotka
01 Jan 2008
View more papers

More From: Clinical Pharmacology & Therapeutics

Paper Title
Journal
Date
Author
-
-
Clinical Pharmacology & Therapeutics | VOL. -
--
01 May 2024
Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis
Haesuk Park ... Ashutosh M. Shukla
Clinical Pharmacology & Therapeutics | VOL. -
Haesuk Park, et. al.Haesuk Park ... Ashutosh M. Shukla
17 Apr 2024
ASCPT News
-
Clinical Pharmacology & Therapeutics | VOL. -
--
17 Apr 2024
Highlights
-
Clinical Pharmacology & Therapeutics | VOL. -
--
17 Apr 2024
View more papers